Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Sep 28

PMID 39334976

Authors

Laura Gras-Martin

Adrian Plaza-Diaz

Borja Zarate-Tamames

Paula Vera-Artazcoz

Olga H Torres

Carla Bastida

Dolors Soy

Jesus Ruiz-Ramos

Affiliations

Soon will be listed here.

Abstract

(1) Background: Knowledge about the behavior of antibiotics in critically ill patients has been increasing in recent years. Some studies have concluded that a high percentage may be outside the therapeutic range. The most likely cause of this is the pharmacokinetic variability of critically ill patients, but it is not clear which factors have the greatest impact. The aim of this systematic review is to identify risk factors among critically ill patients that may exhibit significant pharmacokinetic alterations, compromising treatment efficacy and safety. (2) Methods: The search included the PubMed, Web of Science, and Embase databases. (3) Results: We identified 246 observational studies and ten clinical trials. The most studied risk factors in the literature were renal function, weight, age, sex, and renal replacement therapy. Risk factors with the greatest impact included renal function, weight, renal replacement therapy, age, protein or albumin levels, and APACHE or SAPS scores. (4) Conclusions: The review allows us to identify which critically ill patients are at a higher risk of not reaching therapeutic targets and helps us to recognize the extensive number of risk factors that have been studied, guiding their inclusion in future studies. It is essential to continue researching, especially in real clinical practice and with clinical outcomes.

References

Kovacevic T, Miljkovic B, Mikov M, Stojisavljevic Satara S, Dragic S, Momcicevic D . The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries. Dose Response. 2019; 17(2):1559325819850419. PMC: 6537498. DOI: 10.1177/1559325819850419. View

Petejova N, Martinek A, Zahalkova J, duricova J, Brozmannova H, Urbanek K . Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 158(1):65-72. DOI: 10.5507/bp.2012.092. View

Contejean A, Maillard A, Canoui E, Kerneis S, Fantin B, Bouscary D . Advances in antibacterial treatment of adults with high-risk febrile neutropenia. J Antimicrob Chemother. 2023; 78(9):2109-2120. DOI: 10.1093/jac/dkad166. View

Wang X, Wang Y, Yao F, Chen S, Hou Y, Zheng Z . Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study. Drug Des Devel Ther. 2021; 15:2129-2141. PMC: 8142937. DOI: 10.2147/DDDT.S303497. View

Isla A, Rodriguez-Gascon A, Troconiz I, Bueno L, Solinis M, Maynar J . Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet. 2008; 47(3):173-80. DOI: 10.2165/00003088-200847030-00003. View

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T . Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14(6):498-509. PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2. View

Niibe Y, Suzuki T, Yamazaki S, Uchida M, Suzuki T, Takahashi N . Identification of factors affecting meropenem pharmacokinetics in critically ill patients: Impact of inflammation on clearance. J Infect Chemother. 2022; 28(4):532-538. DOI: 10.1016/j.jiac.2021.12.017. View

De Waele J, Carrette S, Carlier M, Stove V, Boelens J, Claeys G . Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2013; 40(3):380-7. DOI: 10.1007/s00134-013-3187-2. View

Sime F, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker S . Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrob Agents Chemother. 2019; 63(10). PMC: 6761554. DOI: 10.1128/AAC.01265-19. View

10.

Obara V, Zacas C, de Maio Carrilho C, Delfino V . Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients. Rev Bras Ter Intensiva. 2017; 28(4):380-386. PMC: 5225912. DOI: 10.5935/0103-507X.20160071. View

11.

Meenks S, Punt N, le Noble J, Foudraine N, Neef K, Janssen P . Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study. Crit Care. 2023; 27(1):82. PMC: 9982780. DOI: 10.1186/s13054-023-04353-5. View

12.

Alsultan A, Dasuqi S, Aljamaan F, Omran R, Syed S, AlJaloud T . Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia. Saudi Pharm J. 2021; 29(11):1272-1277. PMC: 8596159. DOI: 10.1016/j.jsps.2021.09.017. View

13.

Tangden T, Ramos Martin V, Felton T, Nielsen E, Marchand S, Bruggemann R . The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017; 43(7):1021-1032. DOI: 10.1007/s00134-017-4780-6. View

14.

Galar A, Munoz P, Valerio M, Cercenado E, Garcia-Gonzalez X, Burillo A . Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution. Int J Antimicrob Agents. 2018; 53(1):40-48. DOI: 10.1016/j.ijantimicag.2018.09.015. View

15.

Sime F, Hahn U, Warner M, Tiong I, Roberts M, Lipman J . Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655099. DOI: 10.1128/AAC.00311-17. View

16.

Sinnollareddy M, Roberts M, Lipman J, Peake S, Roberts J . Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. J Antimicrob Chemother. 2018; 73(6):1647-1650. DOI: 10.1093/jac/dky057. View

17.

Ren J, Hou Y, Li J, Gao Y, Li R, Jin X . An evaluation on the association of vancomycin trough concentration with mortality in critically ill patients: A multicenter retrospective study. Clin Transl Sci. 2021; 14(5):1780-1790. PMC: 8504840. DOI: 10.1111/cts.13020. View

18.

Ruiz J, Ramirez P, Company M, Gordon M, Villarreal E, Concha P . Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients. J Glob Antimicrob Resist. 2017; 12:90-95. DOI: 10.1016/j.jgar.2017.09.019. View

19.

Zhao Y, Zou Y, Xiao Y, Wang F, Zhang B, Xiang D . Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. Infect Dis Ther. 2021; 11(1):201-216. PMC: 8847520. DOI: 10.1007/s40121-021-00551-2. View

20.

Chapuis T, Giannoni E, Majcherczyk P, Chiolero R, Schaller M, Berger M . Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010; 14(2):R51. PMC: 2887166. DOI: 10.1186/cc8941. View